Viking Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. Headquartered in San Diego, California, the company focuses on developing novel therapies for metabolic and endocrine disorders. Founded by Brian Lian, Ph.D., Viking has built its identity around metabolism-focused drug discovery, aiming to address large unmet medical needs in obesity, lipid disorders, and liver disease. The company’s leadership and operating footprint remain centered in the United States, with R&D activities anchored in San Diego. ([vikingtherapeutics.com](https://vikingtherapeutics.com/about/?utm_source=openai)) Viking’s most important program is VK2735, a wholly owned dual GLP-1/GIP agonist being advanced for obesity and other metabolic disorders. This asset is the company’s lead strategic driver. In 2025, Viking initiated its VANQUISH Phase 3 registration program for the subcutaneous formulation of VK2735, while also advancing an oral tablet version. The company later reported positive Phase 2 oral data showing meaningful weight loss over 13 weeks, and in 2026 it presented additional oral-program data at the European Congress on Obesity. These developments underscore Viking’s push to compete in a highly attractive but intensely crowded obesity market through differentiation in both mechanism and dosing convenience. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735?utm_source=openai)) Beyond obesity, Viking is developing VK2809, an orally available selective thyroid hormone receptor beta agonist designed for lipid disorders and metabolic liver disease, including MASH/NASH. The company reported encouraging Phase 2b histology data in 2024, which helped reinforce confidence in the broader thyroid receptor beta platform. Viking is also advancing VK0214, another oral TRβ agonist being explored for X-linked adrenoleukodystrophy, highlighting a pipeline that extends beyond a single indication while staying within the company’s core metabolic and endocrine expertise. ([vikingtherapeutics.com](https://vikingtherapeutics.com/pipeline/vk0214/?utm_source=openai)) From a competitive standpoint, Viking is still a development-stage biotech rather than a commercial-stage pharmaceutical company. It competes against larger, better-capitalized players in obesity and metabolic disease, so its investment case depends heavily on clinical execution, regulatory progress, and eventual commercialization or partnership potential. Its portfolio is built around potentially differentiated, small-molecule or peptide-based programs that could offer practical advantages versus incumbent therapies, but the company remains exposed to the typical binary risks of clinical development. ([vikingtherapeutics.com](https://vikingtherapeutics.com/?utm_source=openai)) Recent milestones have been particularly important for the equity story: phase 3 initiation for VK2735, positive oral obesity data, and continued presentation of data across major scientific meetings in 2026. For investors, Viking Therapeutics represents a high-upside U.S. NASDAQ-listed biotech with a focused pipeline, substantial clinical catalysts, and a concentrated risk profile tied to obesity and metabolic-disease readouts. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735?utm_source=openai))